Cargando…

A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

This is a phase 1, open-label, single-sequence, multiple-dose, single-center trial conducted in the US (NCT03790839), to evaluate the clinical pharmacokinetics, safety and pharmacodynamics of dorzagliatin co-administered with sitagliptin in patients with T2D and obesity. The trial has completed. 15...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Li, Zhang, Jiayi, Sun, Yu, Zhao, Yu, Liu, Xiang, Fang, Zhiyin, Feng, Lingge, He, Bin, Zou, Quanfei, Tracey, Gregory J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014962/ https://www.ncbi.nlm.nih.gov/pubmed/36918550 http://dx.doi.org/10.1038/s41467-023-36946-7

Ejemplares similares

Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus
por: Wang, Kun, et al.
Publicado: (2023)

Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator
por: Miao, Jia, et al.
Publicado: (2021)

Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
por: Yu, Yunfeng, et al.
Publicado: (2022)

Fixed drug eruption to sitagliptin
por: Gupta, Mrinal, et al.
Publicado: (2015)

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
por: Yang, Wenying, et al.
Publicado: (2022)

Hypoglycemia associated with off-label sitagliptin use
por: Whitley, Heather P, et al.
Publicado: (2008)

The Pharmacokinetic Profile of Palovarotene: An Open-Label Phase I Trial Investigating the Effect of Food and Potential for Drug–Drug Interaction in Healthy Participants
por: Marino, Rose, et al.
Publicado: (2023)

Off-label drugs for obesity
por: Morgan, Andy, et al.
Publicado: (2022)

Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial
por: Ito, Daisuke, et al.
Publicado: (2021)

Pharmacokinetics and Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Study
por: Shi, Ping, et al.
Publicado: (2021)

Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open‐label, drug–drug interaction study
por: Tachibana, Masaya, et al.
Publicado: (2018)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes
por: Chow, Elaine, et al.
Publicado: (2023)

Renal Function During an Open-Label Prospective Observational Trial of Sitagliptin in Patients With Diabetes: A Sub-Analysis of the JAMP Study
por: Tomonaga, Osamu, et al.
Publicado: (2018)

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study
por: Naimi, Rahim Mohammad, et al.
Publicado: (2021)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2018)

A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors
por: Liao, Mingxiang, et al.
Publicado: (2021)

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single‐center, open‐label phase I trial
por: Deng, Kunhong, et al.
Publicado: (2022)

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
por: Boni, Valentina, et al.
Publicado: (2022)

Triple drug therapy with GABA, sitagliptin, and omeprazole prevents type 1 diabetes onset and promotes its reversal in non-obese diabetic mice
por: Lagunas-Rangel, Francisco Alejandro, et al.
Publicado: (2022)

Measurement of soft tissue drug concentrations in morbidly obese and non-obese patients – A prospective, parallel group, open-labeled, controlled, phase IV, single center clinical trial()
por: Simon, P., et al.
Publicado: (2019)

Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2‐drug cocktail in patients with MET‐dysregulated advanced solid tumours: A phase I, multicentre, open‐label, single‐sequence drug–drug interaction study
por: Grande, Enrique, et al.
Publicado: (2020)

Remimazolam besylate for sedation of postoperative patients in intensive care units: a phase I, open label, dose-finding study
por: Tang, Yun, et al.
Publicado: (2022)

Repurposing anti-diabetic drug “Sitagliptin” as a novel virulence attenuating agent in Serratia marcescens
por: Abbas, Hisham A., et al.
Publicado: (2020)

iADRGSE: A Graph-Embedding and Self-Attention Encoding for Identifying Adverse Drug Reaction in the Earlier Phase of Drug Development
por: Cheng, Xiang, et al.
Publicado: (2022)

Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
por: Acharya, M., et al.
Publicado: (2012)

Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
por: Sakurai, Yuuichi, et al.
Publicado: (2016)

A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
por: Morrison, Gilmour, et al.
Publicado: (2019)

Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
por: Kim, Seokuee, et al.
Publicado: (2014)

Sitagliptin-induced hemolysis
por: Bekur, Ragini, et al.
Publicado: (2010)

Sitagliptin-Associated Angioedema
por: Gosmanov, Aidar R., et al.
Publicado: (2012)

Exorbitant Drug Loading of Metformin and Sitagliptin in Mucoadhesive Buccal Tablet: In Vitro and In Vivo Characterization in Healthy Volunteers
por: Shakir, Rouheena, et al.
Publicado: (2022)

Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes
por: Ji, Ming, et al.
Publicado: (2016)

An open-label phase I dose-finding study of APR-246 in hematological malignancies
por: Deneberg, S, et al.
Publicado: (2016)

Practical Asymmetric Synthesis of Sitagliptin Phosphate Monohydrate
por: Gao, Haoling, et al.
Publicado: (2018)

The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes
por: Kodera, Ryo, et al.
Publicado: (2017)

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
por: Cho, Yong Kyun
Publicado: (2018)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011)

The Biological Impacts of Sitagliptin on the Pancreas of a Rat Model of Type 2 Diabetes Mellitus: Drug Interactions with Metformin
por: Shawky, Lamiaa M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1huc7e8tirv93oqbf0a1pcm8b2